The decision to sell your clinical research site (CRS) is likely driven by a combination of factors, including financial considerations. Understanding how your CRS is valued is crucial in navigating the sale process and ensuring you receive a fair and competitive offer.
This blog post sheds light on the concept of valuation multiples and their application in the current clinical research landscape. Do you have questions about selling your Clinical Research Site? We invite you to book a call with our President and experienced M&A advisor, Gary Behler. Reserve time directly on Gary's calendar.
Market Multiples Explained
A valuation multiple is a financial metric used to estimate the value of a company based on a multiple of its financial performance indicators, in particular earnings before interest, taxes, depreciation, and amortization (EBITDA).
In the context of clinical research site valuations, the most commonly used multiple is the EBITDA multiple. This metric represents the number of times a buyer is willing to pay for each dollar of a CRS's annual EBITDA.
What are the current market multiples for clinical research sites?
While there's no one-size-fits-all answer, current market trends indicate that EBITDA multiples for CRS can range from 6x to 12x. This wide range reflects the influence of several factors on a CRS's valuation:
- Financial Performance: Naturally, a CRS with a strong track record of profitability and consistent revenue growth will command a higher multiple.
- Therapeutic Expertise: Specialization in high-demand therapeutic areas (e.g., oncology, rare diseases) can increase the site's value due to its attractiveness to specific sponsors.
- Geographic Location: CRS location plays a role, with sites in densely populated areas with a diverse patient mix, or those with proximity to major research institutions are typically fetching higher valuations.
- Regulatory Compliance: A strong track record of compliance with regulatory requirements is essential and can enhance a CRS's value.
- Growth Potential: Buyers value CRSs with a clear path for future growth, such as established infrastructure for handling complex trials or potential for expansion into new therapeutic areas. Read our blog post Selling Your Clinical Research Site in a Hot Market with more details on how you can capture a higher valuation.
Important Caveats
Remember that market multiples are just benchmarks, not guarantees. The actual valuation of your CRS will be determined through a comprehensive analysis that considers all the factors mentioned above, along with other unique characteristics of your business. Further, if you engage with an advisor to manage a competitive process with multiple buyers, your multiple is guaranteed to rise versus managing the sale alone.
Seeking Expert Guidance
While understanding market multiples provides a general framework, navigating the complexities of CRS valuation requires specialized expertise. An experienced M&A advisory like Evergreen M&A can:
- Conduct a thorough valuation of your CRS: We will consider all relevant factors and employ sophisticated financial modeling techniques to arrive at an accurate valuation. Our analysts get to the most accurate EBITDA knowing cost synergies from platforms and other cost reductions; this results in buyers bidding off the same number and making offers within a specific range, leading to effective negotiations and higher offers.
- Benchmark your CRS against industry peers: We will compare your site to similar assets that have recently been sold to provide context for your valuation.
- Negotiate effectively with potential buyers: With our deep understanding of the market and deal structuring expertise, we can advocate for the highest possible multiple for your CRS. More importantly, we can advise on the best deal structures for longer financial returns that also align with your professional goals. We can help get you to the right percentage of rolled equity into the platform that will best meet your future personal financial goals.
Learn What Your CRS is Worth
The current market presents an exciting opportunity for CRS owners seeking to capitalize on their investment. However, understanding the nuances of valuation is essential for making informed decisions. By working with a trusted M&A advisor, you can gain valuable insights into your CRS's value and ensure a successful outcome in the sale process.
If you're considering a sale or growth investment from buyers, the first step is to conduct a thorough valuation to see what your CRS is worth. Ask about our valuation services, which we offer in addition to our full process advisory. Reserve time on Gary Behler's calendar, or complete the form below.
SCHEDULE A CALL WITH GARY BEHLER
Why Evergreen M&A?